The reimbursement and cost of acute kidney injury: a UK hospital perspective.

Nephron Clinical Practice Pub Date : 2014-01-01 Epub Date: 2014-02-08 DOI:10.1159/000358435
Nitin V Kolhe, Mohamed T Eldehni, Nicholas M Selby, Christopher W McIntyre
{"title":"The reimbursement and cost of acute kidney injury: a UK hospital perspective.","authors":"Nitin V Kolhe,&nbsp;Mohamed T Eldehni,&nbsp;Nicholas M Selby,&nbsp;Christopher W McIntyre","doi":"10.1159/000358435","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Despite the great interest in acute kidney injury (AKI), there have been very few studies that examined the economic impact and costing methodologies of AKI. We aimed to examine the cost and income of AKI in hospitalised patients over a period of 1 year using the NHS costing system related to that year.</p><p><strong>Methods: </strong>A total of 627 patients discharged between January 2008 and December 2008 with AKI were identified by International Classification of Disease 10 codes (ICD-10). Basic demographic data were collected using the hospital electronic records, and the severity of AKI was classified according to the Acute Kidney Injury Network (AKIN) classification. We calculated the total income and isolated the AKI income related to AKI-specific finished consultant episodes. Then we conducted a patient level costing exercise using relative value units (RVU) to compare the cost of AKI to the actual income.</p><p><strong>Results: </strong>The total spell income for all patients was GBP 1,954,922.7; the mean total income per patient was GBP 3,752.3 (95% CI 3,594.6-3,903.9). AKIN stage 3 generated significantly higher total spell and AKI income. The estimated overall cost of treating AKI was higher than the AKI income to the Primary Care Trust (GBP 1,984,543.9 vs. 1,755,395).</p><p><strong>Conclusion: </strong>AKIN stage 3 has a significant economic impact when compared with AKIN stages 1 and 2. The move towards a patient level costing using RVU could be a more efficient way to match cost and income.</p>","PeriodicalId":19094,"journal":{"name":"Nephron Clinical Practice","volume":"126 1","pages":"51-6"},"PeriodicalIF":0.0000,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000358435","citationCount":"18","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nephron Clinical Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000358435","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2014/2/8 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 18

Abstract

Background: Despite the great interest in acute kidney injury (AKI), there have been very few studies that examined the economic impact and costing methodologies of AKI. We aimed to examine the cost and income of AKI in hospitalised patients over a period of 1 year using the NHS costing system related to that year.

Methods: A total of 627 patients discharged between January 2008 and December 2008 with AKI were identified by International Classification of Disease 10 codes (ICD-10). Basic demographic data were collected using the hospital electronic records, and the severity of AKI was classified according to the Acute Kidney Injury Network (AKIN) classification. We calculated the total income and isolated the AKI income related to AKI-specific finished consultant episodes. Then we conducted a patient level costing exercise using relative value units (RVU) to compare the cost of AKI to the actual income.

Results: The total spell income for all patients was GBP 1,954,922.7; the mean total income per patient was GBP 3,752.3 (95% CI 3,594.6-3,903.9). AKIN stage 3 generated significantly higher total spell and AKI income. The estimated overall cost of treating AKI was higher than the AKI income to the Primary Care Trust (GBP 1,984,543.9 vs. 1,755,395).

Conclusion: AKIN stage 3 has a significant economic impact when compared with AKIN stages 1 and 2. The move towards a patient level costing using RVU could be a more efficient way to match cost and income.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
急性肾损伤的报销和费用:英国医院的观点。
背景:尽管人们对急性肾损伤(AKI)有很大的兴趣,但很少有研究检查AKI的经济影响和成本计算方法。我们的目的是使用与该年相关的NHS成本系统检查住院患者在1年期间的AKI成本和收入。方法:采用国际疾病分类第10号代码(ICD-10)对2008年1月至2008年12月出院的627例AKI患者进行鉴定。使用医院电子病历收集基本人口统计数据,并根据急性肾损伤网络(AKIN)分级对AKI的严重程度进行分级。我们计算了总收入,并分离了与AKI相关的AKI收入。然后,我们使用相对价值单位(RVU)进行了患者水平的成本计算,以比较AKI的成本与实际收入。结果:所有患者的法术总收入为1,954,922.7英镑;每位患者的平均总收入为3,752.3英镑(95% CI 3,594.6-3,903.9)。AKIN阶段3产生了显著更高的法术和AKI总收入。治疗AKI的估计总成本高于初级保健信托的AKI收入(1,984,543.9英镑对1,755,395英镑)。结论:与AKIN 1期和2期相比,AKIN 3期具有显著的经济影响。使用RVU向患者水平成本的转变可能是匹配成本和收入的更有效方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Nephron Clinical Practice
Nephron Clinical Practice 医学-泌尿学与肾脏学
自引率
0.00%
发文量
0
审稿时长
6-12 weeks
期刊最新文献
Comparison of Outcomes of In-Centre Haemodialysis Patients between the 1st and 2nd COVID-19 Outbreak in England, Wales, and Northern Ireland: A UK Renal Registry Analysis Association of Serum Triglycerides and Renal Outcomes among 1.6 Million US Veterans Genetic Deletion of the Stromal Cell Marker CD248 (Endosialin) Protects against the Development of Renal Fibrosis Contents Vol. 128, 2014 Author Index Vol. 127, No. 1-4, 2014
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1